CClinicalTrials.gg
CompletedNCT02499068PROMETEUpdated Aug 6, 2019

Madrid Project on the Management of Chronic Obstructive Pulmonary Disease With Home Telemonitoring

An interventional study of Telehealth in COPD and Disease Progression, sponsored by Arturo Garcia. Completed at 5 sites in Spain. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-08-06.

Sponsored by Arturo Garcia · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Study summary

The purpose of the study is to verify the clinical effectiveness of a managed home telemonitoring program in patients with severe COPD against usual clinical practice, as measured by the decrease in the number of exacerbations, number of hospitalizations, hospital days and emergency room visits in a 12 month period

The primary endpoint of effectiveness is "severe exacerbations avoided."

The main hypothesis is that patients with severe or very severe COPD patients managed with a home telehealth program have better outcomes than patients managed according to usual clinical practice.

Read the detailed description

Randomized, controlled, multicenter, performance, cost assessment and economic evaluation clinical trial. An arm of the trial will consist of patients assigned to the intervention group (telehealth group: TG ), and the other arm will consist of patients randomized to the control group (routine clinical practice: RCP).

For the economic evaluation, the perspective of the health system will be used. Therefore it only direct costs will be considered. In the TG arm also intervention costs it will be considered.

Patient selection:

Responsible researcher at each hospital center will coordinate the patient selection process. The researchers will identify candidate patients screening through hospital medical records.

After this first screening, patients will be contacted and invited to participate in the study. In a personal interview, the researcher explains the study to the patient and deliver the information sheet, verifying that patient meets all inclusion/exclusion criteria, obtains informed consent and then proceeds to patient randomization. To avoid bias from exclusions, researchers will hold record with patient exclusion causes.

Every hospital centers will include on average 60 patients (30 in each arm). The inclusion of patients will be competitive; having centers including patients in the study until reaching the final sample size of 120 patients per arm.

Randomization:

To avoid selection bias, patients assigned to each group will be randomized. To ensure that the number of subjects in each arm is the same, a restrictive block randomization is performed. Randomization is performed using random number generation by computer and the block size of 10 units.

Home Telehealth program:

Vital sign devices being used: spirometer, pulse oximeter with capacity for heart rate monitor, blood pressure, Visionox® (device capable of measuring respiratory rate, compliance with the hours of oxygen, and the flow and pattern of oxygen used).

Devices send data automatically to a modem by Bluetooth. Modem receives and transmits data simultaneously from the monitoring devices to a Central Monitoring Center (CMC). Data received by the modem are encrypted and sent to the telehealth monitoring platform via a 3G signal.

The CMC is manned by registered nurses and operates during office hours, 7 days a week.

Nurses will attend the patient's home for: the installation of the telehealth devices; to perform a thorough training of the patients / caregivers in the use of equipment and the COPD telehealth program.

Patients will perform daily vital sign measurements at the same time, at rest, after administration of the medication and the pattern of oxygen used. Visionox® performs measurements of respiratory rate and oxygen adherence automatically.

Measured data will be monitored on a daily bases by the nurses at the CMC. CMC will follow-up information, filter for fle positives and false negatives, and use an application acting as a traffic light system:

  • Green: meant that measurements had been taken and were within the predefined limits, and no further action was required.
  • Yellow: "technical alert". This means that the measurements had not been taken or had not been received. This alert could lead to a "clinical alert" due to a lack of adherence or discouragement. When the parameters were not received the nurse at the CMC called the patient to find the reason behind the alert, and either ruled out medical causes or, if one, notified the researcher leading the study.
  • Red: "clinical alert". Meant that a measurement exceeded the limits that were previously preestablished for each.

Classification of severity of clinical alerts is performed by the CMC according to an algorithm. Depending n severity different early medical interventions are taken, or escalated to clinical responsible for early intervention.

02

Conditions studied

03

In context

Lung Diseases, Obstructive

2,592 studies on the registry are indexed under Lung Diseases, Obstructive; 198 are open to participants now.

This study's enrollment of 237 is above the median of 66 across 1,837 interventional studies indexed under Lung Diseases, Obstructive.

Browse Lung Diseases, Obstructive studies →

Lead sponsor

This is the only study on the registry with Arturo Garcia as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Being over 50 and under 90 years of age.
  • Being diagnosed with COPD according to the criteria of GesEPOC, with severe airflow obstruction defined as a forced expiratory volume in one second (FEV1) less than 50% of theoretical.
  • "Exacerbator phenotype" defined as COPD patients having two or more moderate or severe exacerbations per year (GesEPOC guide). These exacerbations should be separated by at least 4 weeks after the end of previous treatment or 6 weeks from the start in cases that have not been treated
  • Clinically stable condition, defined as 6 weeks without clinical symptoms since the last exacerbation of COPD.
  • Having home oxygen therapy.
  • Sign the informed consent.

Exclusion criteria

Exclusion Criteria:

  • Inability of the patient or caregiver to understand the procedure of Telehealth program.
  • Have a life expectancy of less than one year.
  • Have terminal heart failure (NYHA functional class III-IV).
  • Having advanced renal insufficiency (creatinine clearance \<30%) or be on dialysis program.
  • Have liver cirrhosis or be included in a program of liver transplantation.
  • Be institutionalized or in Residential hospice care.
  • Having a mini-mental test-score less than 24, because this score suggests dementia
  • To be considered by your doctor as not comply the treatment or monitoring required by their lung disease.
  • Failure to meet any of the inclusion criteria.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
237 participants (actual)

Study arms

  • Experimental
    COPD, Telehealth

    Patients randomized to this arm would be followed by home telehealth devices and monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.

    Device: Telehealth

  • No intervention
    COPD, Normal clinical practice

    Patients would do the usual clinical practice.

Interventions

  • DeviceTelehealth

    Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.

    Also known as: Telemedicine

06

What researchers measure

Primary outcomes

  1. Number of hospitalizations due to exacerbation of COPD avoided

    Time frame: 1 year

Secondary outcomes

  1. Cost-efficiency of treatment

    Time frame: 1 year

  2. Cost-utility of treatment

    Time frame: 1 year

  3. satisfaction of both patients and clinician responsibility questionnaire

    Time frame: 1 year

07

Study locations

5 sites
  • Hospital Universitario La Princesa
    Madrid, 28006, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Rey Juan Carlos
    Madrid, 28933, Spain
08

References and documents

Publications

  • Segrelles Calvo G, Gomez-Suarez C, Soriano JB, Zamora E, Gonzalez-Gamarra A, Gonzalez-Bejar M, Jordan A, Tadeo E, Sebastian A, Fernandez G, Ancochea J. A home telehealth program for patients with severe COPD: the PROMETE study. Respir Med. 2014 Mar;108(3):453-62. doi: 10.1016/j.rmed.2013.12.003. Epub 2013 Dec 16. PubMed 24433744 ↗
  • Ancochea J, Garcia-Rio F, Vazquez-Espinosa E, Hernando-Sanz A, Lopez-Yepes L, Galera-Martinez R, Peces-Barba G, Perez-Warnisher MT, Segrelles-Calvo G, Zamarro C, Gonzalez-Ponce P, Ramos MI, Conforto JI, Jafri S, Soriano JB. Efficacy and costs of telehealth for the management of COPD: the PROMETE II trial. Eur Respir J. 2018 May 30;51(5):1800354. doi: 10.1183/13993003.00354-2018. Print 2018 May. No abstract available. PubMed 29599185 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02499068
Lead sponsor
Arturo Garcia
Collaborators
Linde Health Care, Técnicas Avanzadas de Investigación en Servicios de Salud TAISS, Syreon Corporation
Responsible party
Arturo Garcia (Fundación Teófilo Hernando, Fundación Teófilo Hernando, Spain) — Sponsor-investigator
First posted
Jul 15, 2015
Start date
Dec 2013
Primary completion
Jun 1, 2016
Completion
Jun 1, 2016
Last update
Aug 6, 2019

Study contacts

Julio Ancochea Bermúdez, MD, PhD
principal investigator · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion